Project Grant R01NS138611
- This federal Project Grant award of $654,287.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The goal of the project is to develop a computational model of neurocognitive impairment in multiple sclerosis (MS), focusing on updating the outdated framework used to characterize cognition in MS. The project aims to leverage cognitive psychology and...
- This $198,928 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The grant will support research at the University of California, San Francisco to elucidate the cellular mechanisms underlying central nervous system injury and progression in multiple sclerosis. Key objectives include determining the role of astrocyte response,...
- This $233,250 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund research at The Washington University to investigate the potential of hyperpolarized 13C magnetic resonance spectroscopic imaging (HP 13C MRSI) and ultra-short echo time magnetization transfer (UTE-MT) imaging to non-invasively study the role of lactate metabolism and...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $742,352 to New York University School of Medicine to conduct the "Childhood Adversity Research Effort in Multiple Sclerosis (CARE.IN.MS)" study. The goal of this multi-year research project is to collaboratively develop and execute a comprehensive, culturally-informed...
- This Project Grant award of $305,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of stem-like T cells in multiple sclerosis (MS) disease progression. The key objectives are to: Rigorously test the hypothesis that a continuing stemness and differentiation of CD4+ T stem cells results in functional and transcriptomic diversification under evolving...
- This Project Grant award of $429,514 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the regulation of myelin in the adult central nervous system. The primary objectives are to: Determine the activity dependence of myelin acquisition in the adult spinal cord. Investigate how tuberous sclerosis complex (TSC) signaling regulates myelin...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is providing $426,938 to Virginia Commonwealth University to explore the role of a novel glutamate-driven signaling pathway initiated in maturing oligodendrocytes through the glutamate transporter GLT-1/EAAT2. This research aims to characterize the mechanisms downstream of...
- This federal Project Grant award of $427,104.00, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on identifying biomarkers of demyelination and remyelination in a mouse model of multiple sclerosis (MS). The key objectives are to profile proteins and lipids in tissue-derived and plasma-derived extracellular vesicles to discover novel biomarkers...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $104,433 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Washington University in St. Louis to conduct research on examining microglia reactivation in multiple sclerosis (MS). The project aims to define the gene signature of disease-associated microglia (DAM) and understand how the function of these cells is affected by repeated activation, as...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund the development of an in vitro platform to investigate the role of matrix metalloproteinase-9 (MMP-9) in blood-brain barrier permeability and neurovascular unit dysfunction in multiple sclerosis (MS). The $534,964 award to Michigan State University aims to enhance understanding of...
CORTICAL DEMYELINATION AND REPAIR IN EARLY MULTIPLE SCLEROSIS. - PROJECT SUMMARY/ABSTRACT MULTIPLE SCLEROSIS (MS) IS AN IMMUNE-MEDIATED, DEMYELINATING DISORDER OF THE CENTRAL NERVOUS SYSTEM (CNS) AND A LEADING CAUSE OF DISABILITY IN YOUNG ADULTS. MS WHITE MATTER LESIONS ARE EASILY VISIBLE ON CLINICAL MAGNETIC RESONANCE IMAGING (MRI) AND ARE THE TARGET OF CURRENT TREATMENTS. HOWEVER, WHITE MATTER LESIONS ARE POOR PREDICTORS OF DISABILITY, AND PREVENTION OF WHITE MATTER LESION FORMATION DOES NOT STOP GRADUAL DISABILITY WORSENING IN LATER STAGES OF DISEASE, WHEN WHITE MATTER LESION FORMATION IS RARE. CORTICAL LESIONS ARE ALSO COMMON IN MS, CAN BE EXTENSIVE, AND ARE ASSOCIATED WITH DISABILITY AND DISABILITY WORSENING OVER TIME. CORTICAL LESIONS ARE THOUGHT TO FORM DUE TO OVERLYING MENINGEAL INFLAMMATION AND THUS THEY MAY RESPOND DIFFERENTLY TO TREATMENT THAN WHITE MATTER LESIONS, IN WHICH INFLAMMATORY MEDIATORS COME FROM PARENCHYMAL VEINS. HERE WE PROPOSE TO FURTHER OUR UNDERSTANDING OF MS CORTICAL LESION FORMATION AND REPAIR IN EARLY MS, THE IMMUNOLOGICAL MECHANISMS UNDERLYING THESE PROCESSES, AND THE IMPACT OF THESE PROCESSES ON THE CLINICAL COURSE OF DISEASE. NEW MRI METHODS APPLIED AT ULTRA-HIGH FIELD STRENGTH (7 TESLA, T), SOME OF WHICH WE HELPED TO DEVELOP, NOW ALLOW US TO SENSITIVELY VISUALIZE CORTICAL LESIONS IN VIVO AND TRACK THEIR FORMATION AND REPAIR. WITH THESE METHODS, WE AND OTHERS HAVE DEMONSTRATED THAT CORTICAL LESIONS ARE COMMON, EVEN EARLY IN DISEASE, AND ARE ASSOCIATED WITH DISABILITY. WE HAVE ALSO FOUND THAT CORTICAL LESION BURDEN, BUT NOT WHITE MATTER LESION BURDEN, PREDICTS SUBSEQUENT WORSENING OF MOTOR DISABILITY. OUR RECENT DATA DEMONSTRATE THAT CORTICAL LESION FORMATION IS RARE IN LONGSTANDING DISEASE, AND SO WE HYPOTHESIZE THAT CORTICAL LESIONS FORM EARLY IN DISEASE AND THEN LEAD TO SUBSEQUENT GRADUAL WORSENING OF DISABILITY OVER TIME. HERE, WE PROPOSE TO FOLLOW A COHORT OF ADULTS WITH NEWLY DIAGNOSED MS FOR 3 YEARS WITH 7T MRI (INCLUDING 0.5MM3 T1 AND MOTION AND B0-CORRECTED T2* WEIGHTED IMAGING), MOTOR AND COGNITIVE EVALUATION, AND BLOOD COLLECTION AT BASELINE, YEAR 1, AND YEAR 3. A SUBSET OF PARTICIPANTS WILL ALSO UNDERGO CEREBROSPINAL FLUID (CSF) COLLECTION AT BASELINE. WE WILL DETERMINE HOW CORTICAL AND WHITE MATTER DEMYELINATION ARE RELATED IN EARLY MS AND THEIR RELATIVE CONTRIBUTIONS TO PHYSICAL AND COGNITIVE DISABILITY AND DISABILITY WORSENING OVER TIME (AIM 1). USING ANNUAL MRI DATA AS WELL AS DATA FROM SHORT INTERVAL MRI FOLLOW-UP (BASELINE, MONTH 3, MONTH 6) IN A SUBSET OF PARTICIPANTS, WE WILL MEASURE CHANGES IN CORTICAL LESIONS OVER TIME AND CHARACTERIZE CORTICAL LESION GROWTH, REPAIR, AND CHRONIC INFLAMMATION (AIM 2). FINALLY, WE WILL USE SINGLE CELL TRANSCRIPTOMICS, PROTEOMICS, AND FLOW CYTOMETRY IN BLOOD AND CSF TO DETERMINE HOW CORTICAL LESION BURDEN IS RELATED TO IMMUNE ACTIVATION IN THE PERIPHERY AND THE CNS (AIM 3). THIS WORK WILL LEAD TO KEY ADVANCES IN OUR UNDERSTANDING OF THE PATHOPHYSIOLOGY, NATURAL HISTORY, AND CLINICAL IMPLICATIONS OF CORTICAL LESIONS IN EARLY MS, WHICH WILL BE ESSENTIAL THE FUTURE DEVELOPMENT AND TESTING OF TREATMENTS TARGETING CORTICAL LESION FORMATION AND REPAIR.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $670.1k | 7/11/25 | ||
| Not listed | $667.6k | 7/29/24 |